Clinical Research Directory

Inclusion Criteria: * Patient, male or female (under effective contraception if premenopausal) over 18 years old * Patient affiliated with a social security plan * Patient able to understand and follow the instructions of the study * Patient having signed an informed consent * Patient having a central macular thickness greater than 320μm (Spectral Domain, 270µm Time Domain) * Patient with an inflammatory macular edema, unilateral or bilateral (in the case of a bilateral inflammatory macular edema, the eye most affected will be treated) Exclusion Criteria: * Patient with an infectious uveitis * Patient with uncontrolled active infection * Patient receiving an unbalanced general anti-inflammatory and/or immunosuppressive and/or immunomodulatory therapy (recent modification \<1 month) * Patient having a history of glaucoma and/or ocular hypertension in the eye studied (intraocular pressure (IOP) \> 25 mmHg without antiglaucoma medication or \> 21 mmHg with antiglaucoma combination therapy) and/or cortisone-causing-hypertension not controlled by an antiglaucoma dual therapy * Patient with uncontrolled diabetes (HbA1c\> 8%) or unbalanced hypertension (Systolic Blood Pressure \> 160 mmHg and/or Diastolic Blood Pressure \> 100mmHg) * Edematous diabetic maculopathy * Patient who had received triamcinolone (subconjunctivally or sub-tenon) 3 months before randomization, or 700μg dexamethasone intravitreally 6 months before randomization * Suspected or active ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, such as active epithelial keratitis with herpes simplex (dendritic keratitis), vaccinia, varicella, mycobacterial infections and mycoses * History of ocular herpes infection or central serous chorioretinopathy * Aphakic eye with rupture of the posterior lens capsule * Eye with implant in the anterior chamber, iris- or transscleral-fixated intraocular implant and rupture of the posterior lens capsule * Uncontrolled systemic inflammatory disease. * Known hypersensitivity to the active substance or to one of the excipients of Ozurdex®, Kenacort® or injectable fluorescein * Pregnant woman or likely to become pregnant or nursing * Patient participating in another clinical trial * Adult under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")